On March 23, 2017 GlobeImmune, Inc. reported it has entered into a definitive purchase agreement for the sale of 12,835,490 shares of its common stock to NantCell, Inc., a member of the NantWorks ecosystem of companies (Press release, GlobeImmune, MAR 23, 2017, View Source [SID1234528328]). In connection with the sale of its common stock, NantCell has agreed to pay GlobeImmune $100,000 in cash and issue to GlobeImmune 200,000 shares, an estimated $2.0 million in value, of NantCell’s common stock.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"We are pleased to enter into this strategic agreement with NantCell," said Timothy C. Rodell, M.D., Chairman of GlobeImmune. "We believe that, with NantCell’s resources, this combination could leverage GlobeImmune’s Tarmogen technology platform to accelerate development of our programs in oncology and infectious disease," continued Dr. Rodell.

"GlobeImmune has continued to impact the oncology industry by putting innovative drug candidates forward to treat cancer and infectious diseases," said Dr. Patrick Soon-Shiong, founder of NantCell. "In our mission to win the war against cancer, our team welcomes opportunities to engage with companies who are revolutionizing cancer care and treatments. We are looking forward to leveraging the expertise of GlobeImmune."